These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 25346505)

  • 1. Predictors of abstinence from heavy drinking during treatment in COMBINE and external validation in PREDICT.
    Gueorguieva R; Wu R; O'Connor PG; Weisner C; Fucito LM; Hoffmann S; Mann K; O'Malley SS
    Alcohol Clin Exp Res; 2014 Oct; 38(10):2647-2656. PubMed ID: 25346505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of abstinence, no heavy drinking days, and a 2-level reduction in World Health Organization drinking levels during treatment for alcohol use disorder in the COMBINE study.
    Wallach JD; Gueorguieva R; Phan H; Witkiewitz K; Wu R; O'Malley SS
    Alcohol Clin Exp Res; 2022 Jul; 46(7):1331-1339. PubMed ID: 35616436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate.
    Gueorguieva R; Wu R; Tsai WM; O'Connor PG; Fucito L; Zhang H; O'Malley SS
    Eur Neuropsychopharmacol; 2015 Oct; 25(10):1586-99. PubMed ID: 26141511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment.
    Gueorguieva R; Wu R; Donovan D; Rounsaville BJ; Couper D; Krystal JH; O'Malley SS
    Alcohol; 2012 Mar; 46(2):121-31. PubMed ID: 21925828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of drinking goal on treatment outcome for alcoholism.
    Bujarski S; O'Malley SS; Lunny K; Ray LA
    J Consult Clin Psychol; 2013 Feb; 81(1):13-22. PubMed ID: 23231573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study.
    Gueorguieva R; Wu R; Donovan D; Rounsaville BJ; Couper D; Krystal JH; O'Malley SS
    Drug Alcohol Depend; 2010 Mar; 107(2-3):221-9. PubMed ID: 19969427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.
    Mann K; Lemenager T; Hoffmann S; Reinhard I; Hermann D; Batra A; Berner M; Wodarz N; Heinz A; Smolka MN; Zimmermann US; Wellek S; Kiefer F; Anton RF;
    Addict Biol; 2013 Nov; 18(6):937-46. PubMed ID: 23231446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study.
    Greenfield SF; Pettinati HM; O'Malley S; Randall PK; Randall CL
    Alcohol Clin Exp Res; 2010 Oct; 34(10):1803-12. PubMed ID: 20645934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Who achieves low risk drinking during alcohol treatment? An analysis of patients in three alcohol clinical trials.
    Witkiewitz K; Pearson MR; Hallgren KA; Maisto SA; Roos CR; Kirouac M; Wilson AD; Montes KS; Heather N
    Addiction; 2017 Dec; 112(12):2112-2121. PubMed ID: 28511286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling longitudinal drinking data in clinical trials: an application to the COMBINE study.
    DeSantis SM; Bandyopadhyay D; Baker NL; Randall PK; Anton RF; Prisciandaro JJ
    Drug Alcohol Depend; 2013 Sep; 132(1-2):244-50. PubMed ID: 23566774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?
    Maisel NC; Blodgett JC; Wilbourne PL; Humphreys K; Finney JW
    Addiction; 2013 Feb; 108(2):275-93. PubMed ID: 23075288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moderating effects of a craving intervention on the relation between negative mood and heavy drinking following treatment for alcohol dependence.
    Witkiewitz K; Bowen S; Donovan DM
    J Consult Clin Psychol; 2011 Feb; 79(1):54-63. PubMed ID: 21261434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alcohol Use Disorder Treatment: The Association of Pretreatment Use and the Role of Drinking Goal.
    Berger L; Brondino M; Fisher M; Gwyther R; Garbutt JC
    J Am Board Fam Med; 2016; 29(1):37-49. PubMed ID: 26769876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabis use during treatment for alcohol use disorders predicts alcohol treatment outcomes.
    Subbaraman MS; Metrik J; Patterson D; Swift R
    Addiction; 2017 Apr; 112(4):685-694. PubMed ID: 27865015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Abstinence From Heavy Drinking During Follow-Up in COMBINE.
    Gueorguieva R; Wu R; Fucito LM; O'Malley SS
    J Stud Alcohol Drugs; 2015 Nov; 76(6):935-41. PubMed ID: 26562602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does family history of alcoholism moderate naltrexone's effects on alcohol use?
    Capone C; Kahler CW; Swift RM; O'Malley SS
    J Stud Alcohol Drugs; 2011 Jan; 72(1):135-40. PubMed ID: 21138720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.
    Falk DE; O'Malley SS; Witkiewitz K; Anton RF; Litten RZ; Slater M; Kranzler HR; Mann KF; Hasin DS; Johnson B; Meulien D; Ryan M; Fertig J;
    JAMA Psychiatry; 2019 Apr; 76(4):374-381. PubMed ID: 30865232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients.
    Verheul R; Lehert P; Geerlings PJ; Koeter MW; van den Brink W
    Psychopharmacology (Berl); 2005 Mar; 178(2-3):167-73. PubMed ID: 15322728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between medication adherence and treatment outcomes: the COMBINE study.
    Zweben A; Pettinati HM; Weiss RD; Youngblood M; Cox CE; Mattson ME; Gorroochurn P; Ciraulo D
    Alcohol Clin Exp Res; 2008 Sep; 32(9):1661-9. PubMed ID: 18616687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study.
    Gueorguieva R; Wu R; Donovan D; Rounsaville BJ; Couper D; Krystal JH; O'Malley SS
    Alcohol Clin Exp Res; 2011 Mar; 35(3):523-31. PubMed ID: 21143249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.